ProShares Ultra NASDAQ Biotechnology
26 hedge funds and large institutions have $22.9M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 8 closing their positions.
284% more capital invested
Capital invested by funds: $5.97M → $22.9M (+$17M)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
28% more call options, than puts
Call options by funds: $5.02M | Put options by funds: $3.93M
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
8.44% more ownership
Funds ownership: 3.51% → 11.94% (+8.4%)
4% more funds holding
Funds holding: 25 → 26 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$5.4M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.18M |
| 3 |
HF
HRT Financial
New York
|
+$1.95M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.33M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$884K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$1.97M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$97.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$52.7K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$49K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
26
IFP Advisors
Tampa,
Florida
| $8K | – | – | – |
|
|
CIC
27
Chase Investment Counsel
Charlottesville,
Virginia
| – | -$1.97M | -46,396 | Closed |
|
|
28
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$49K | -1,145 | Closed |
|
|
TC
29
Truvestments Capital
Sarasota,
Florida
| – | -$32K | -750 | Closed |
|
|
EW
30
Evoke Wealth
Los Angeles,
California
| – | -$29.8K | -700 | Closed |
|
|
ASN
31
Advisory Services Network
Atlanta,
Georgia
| – | -$35K | -671 | Closed |
|
32
Simplex Trading
Chicago,
Illinois
| – | -$14K | -331 | Closed |
|
33
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$8K | -180 | Closed |
|
34
Citigroup
New York
| – | -$5K | -120 | Closed |
|
BIB Hedge Fund Activity: Q4 2019 in Review
26 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2019, worth a combined $22.9M — up 284% from $5.97M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BIB positions and 8 closed out — a net gain of 1 holder — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Geneos Wealth Management, adding an estimated $5.4M. The largest seller was Chase Investment Counsel, exiting entirely with an estimated $1.97M sold.
- 26 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2019, up from 25 in Q3 2019.
- Funds reported $22.9M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2019, up 284% quarter-over-quarter.
- 9 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2019 and 8 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2019 was Geneos Wealth Management, an estimated $5.4M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2019 was Chase Investment Counsel, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2019.